
Concord Biotech Ltd is Rated Sell
2026-05-19 10:11:09Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read MoreAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript
07-Aug-2026 | Source : BSETranscript of Q1 - FY27 Earnings call held on August 03 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
03-Aug-2026 | Source : BSEThe audio recording of the conference held on August 03 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3
Announcement under Regulation 30 (LODR)-Newspaper Publication
01-Aug-2026 | Source : BSENewspaper publication cutouts of unaudited Standalone and Consolidated Financial results for the first quarter ended June 30 2026
Corporate Actions
No Upcoming Board Meetings
Concord Biotech Ltd has declared 755% dividend, ex-date: 24 Jul 26
No Splits history available
No Bonus history available
No Rights history available